Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIAZFP)

Drug Name
BBP-631 Drug Info
Indication
Disease Entry ICD 11 Status REF
Congenital adrenal hyperplasia 5A71.01 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMIAZFP

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Steroid 21-hydroxylase (CYP21A2) TTP4GLG CP21A_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT04783181) A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of the Safety and Efficacy of Gene Therapy for Congenital Adrenal Hyperplasia Through Administration of an Adeno-Associated Virus (AAV) Serotype 5-Based Recombinant Vector Encoding the Human CYP21A2 Gene. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Adrenas Therapeutics